Anteo Technologies - New York presentation 2015

Anteo Diagnostics Limited (ASX:ADO)

March 2015

Presented by Dr Geoff Cumming

CEO

Forward Looking Statement

The purpose of the presentation is to provide an update of the business of Anteo Diagnostics (ASX:ADO). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by Anteo and should not be relied upon as an independent source of information. Please contact Anteo and/or refer to the Company's website for further information.

The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information.

Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Anteo Diagnostics Ltd ’ s control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and Anteo’s current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution.

This presentation should not be relied on as a recommendation or forecast by Anteo Diagnostics Limited. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

Anteo Diagnostics Limited I Investor Presentation 2

Anteo Company Profile

An Australian biotechnology company that develops, manufactures and commercialises proprietary surface coatings for health care, life sciences and beyond.


Mix&Go™

BiosensorsMembranes Microarrays Microtitre plates

Particles

The surface you want on the surface you have.

Financial Snapshot – March 2015

Executive Team Dr. Geoff Cumming – Chief Executive Officer Dr. Joe Maeji – Chief Scientific Officer Mr. Richard Martin – Chief Financial Officer Dr. Tina Baumgartner – VP of Business Development Mr. Joshua Soldo – VP of Scientific Affairs Dr Rachel de las Heras – Head Commercial Development Mr. Shaun Cooper – Head of Production

Board of Directors

Mr. Mark Bouris Non-Executive Chairman

Dr. Geoff Cumming Chief Executive Officer

Mr. Richard Martin Executive Director

Ms. Sandra Andersen Non-Executive Director

Dr. John Hurrell Non-Executive Director


Shareholders 5,019 First Cape Mgt Pty Ltd 9.4%

Austcorp 190 Pty Ltd 3.9%

Nimrod Finance Ltd 2.4%

Corporate Snapshot

ASX ADO

Cash $6.8M

Market Cap. $78M

Av Daily Volume (30 d) 1,378,989

52 week high/low $0.28/$0.09

Shares on issue 844.8M

Top 20 29.78%

Directors/Staff 16%

Diagnostic Industry Drivers

Health Economics Point-of-Care Testing PERCENT OF WW HEALTHCARE SPENDING USED ON DIAGNOSTICS

PERCENT OF MEDICAL DECISION-MAKING INFLUENCED BY DIAGNOSTICS

DIAGNOSTIC TESTING MOVES FROM THE LABORATORY

TO THE POINT OF CARE

2% 70%

Diagnostics = critical medical decision-making

•  better patient outcomes •  lives saved •  reduced health care costs

Diagnostic test are moving closer to the: •  patient •  physician’s office •  emergency vehicles •  assisted living facilities •  patient’s home


Cost Savings Miniaturisation

Mix&Go-The Secret Sauce


•  Ease of use •  Performance •  Cost

•  Manufacturability

Improves what’s possible; and makes the impossible accessible

Platform Technology: Mix&Go Value Creation

Mix&Go™ is a universal double-sided molecular velcro:

The Mix&Go Difference


•  Uniquely suited for applications in diagnostics and life sciences •  Binds fragile biomolecules gently yet strongly to synthetic surfaces •  Addresses critical bottlenecks in test development: •  Miniaturisation for point-of-care •  Pressure to save cost in test development and manufacture •  Family of products, over 50 formulations for different applications

Value Capture

Anteo participates in the value it creates to its partners. The company has different revenue streams:

Value Creation Licensing:

•  Development Fees •  License or Technology Access Fees •  Royalties on sales from products containing Mix&Go

Value Capture

R&D Agreements: •  Paid R&D undertaken on partner’s behalf

OEM and Supply Agreements: •  In house manufacture of Mix&Go-enhanced products •  For B2B customers

AMG Products and Services: •  Sales revenues •  Provide easy way to experience the Mix&Go advantages •  Provides partner with access to broad technical expertise


Growth Strategy


Anteo is implementing a five part growth strategy:

•  Licensing Anteo’s IP •  Expanding Anteo’s Core Competencies & IP

•  Developing Anteo’s Product Pipeline

•  Exploring Anteo’s Blue Sky Opportunities •  Acquisition of Synergistic Assets

Shareholder Value

Licensing Anteo’s IP - Example – PoC Device

Breathing life into a challenging project …

• • • • • • • • • •

Global, well-known diversified company (2013 healthcare revenues: €10B) Initial application: critical care – cardiac function Six years in development Clinically necessary performance not achieved Pilot study with Mix&Go showed promise 12 month paid engagement to optimize one of two Achieved clinical benchmark

system components

Demonstrated significant improvement on second component Now engaged in paid project to optimize system holistically Projected launch: 2015

Expectation: royalties on every test performed on the instrument


Licensing IP - Anteo’s Future Opportunities

Large global healthcare markets underpin revenue growth potential

Anteo is targeting a number of diverse large and growing healthcare sectors with Mix&Go. The compelling market opportunities include:

•  Bioseparations •  Laboratory Diagnostics •  Point-of-Care

• Rapid Test Products • Life Science R&D

The total market size of these fields is in excess of $50B


Expanding Anteo’s Core Competencies & IP


AIM – To coat any surface in any format 1.  Particles

ü  Control protein density & particle uniformity

ü  Especially Nanoparticles (< 1 µm and specialising in <100 nm)

2.  Planar Surfaces ü  Coat common surfaces used in life sciences regardless of hydrophobicity/

hydrophilicity profile

3.  Mix&Go Library ü  25-50 new formulations

ü  Mix&Go for hydrophobic surfaces

ü  Cheaper Mix&Go for industrial applications

ü  Safer Mix&Go for in-vivo applications

Competencies together support Licensing & Blue Sky applications

Expanding Anteo’s Core Competencies & IP


Level 1: Positioning

Level 2: Developing Core Competency (IP and Know How)

IP Strategy

ü  Generation of Surface Coating Diversity. Granted. Ø  Methods to generate libraries of different surfaces and screening thereof

ü  Use of Metal Complexes. Granted and US Divisional filed. Ø  Use of metal complexes to bind proteins to surfaces

ü  Binding Systems. National Phase. Ø  Use of metal polymers as coatings

ü  Method to remove or decrease interference in a sample. ü  PoC1 sensor surface could further improve outcomes with the device.

ü  Coating Nanoparticles. Ø  Conjugating Molecules to Particles. PCT Phase.

ü  Coating New Materials: new thermoplastics, steel, etc. Ø  Heterofunctional Binding Systems. Provisional Phase.

Developing Anteo’s Product Pipeline


AIM – To demonstrate stable and effective products can be made and sold on the Mix&Go surface

1. Mix&Go Solutions ü  Mix&Go Sub-micron, Micro and Biosensor

ü  Mix&Go Plates & Mix&Go In-Vivo

2. Novel Mix&Go products ü  AMG - Streptavidin coated plates and magnetic particles

ü  AMG – Coupling Kit (magnetic beads 1 µm)

ü  AMG – Activation Kit (latex particles 100-400 nm)

ü  AMG – Coupling Kit (gold particles 40 nm)

ü  AMG - Protein A/G/L Filtration Plate (bio-separations)

Builds technology and brand awareness. $$ & knowledge acquired supports Core Competencies & Licensing

Exploring Anteo’s Blue Sky Opportunities


Exploring Anteo’s Blue Sky Opportunities

Not one market but multiple multi-billion $ markets

Attractive opportunities exist for Anteo •  Several applications in cleantech and resources under evaluation in

collaboration with domain experts.


Bioseparations: Ø  Purification of a biological material from mixture Ø  Mix&Go can bind to:

•  bacteria, viruses, toxic metals, various capture agents

Ø  Combined with: •  Simple, cost effective magnetic separations

and membrane technologies.

Purification: Water treatment, recycling oils, removing radio-isotopes

In Vivo: Ø  Scaffolds (bone, artery, cartilage

replacement) Ø  Wound dressings (sealants, artificial

membranes) Ø  Drug delivery (drug eluting stents) Ø  Implants (TiO2, IrO2 used as coatings

on vascular stents)

Acquisition of Synergistic Assets


Anteo is investigating the acquisition of companies that will help act as a catalyst for commercialisation of Mix&Go.

Three key criteria: ü  Cash Flow Positive ü  Accretive and ü  Technological Fit

Advisor appointed – reviewing opportunities

Planned Milestones for 2015 2015 2016


Advancing near-term value accretive opportunities that will translate quickly into revenue….

ü  Feasibility agreement w/ global healthcare company for development of Point of Care device

ü  Entered into a paid Research and Collaboration Agreement with IMRA

ü  Strengthening existing partner relations by co-developing and co-marketing products ü  Negotiations advancing with medical device company, extending our opportunities into in Vivo

ü  Two additional paid Research and Collaboration projects undertaken during the Q1 of CY 2015

ü  Mix&Go integrated in 100+ products at partner company ü  Continue to launch 1 product/ quarter

ü  Adding distribution partners for Anteo’s Mix&Go and AMG product lines

ü  Advancing a proprietary product concept with large industry-wide potential

ü  Generating custom M&G formulations optimized for various surfaces and applications ü  New patent application continues to build Anteo’s suite of patents using Mix&Go

Ø  Latest application builds on previously filed patents and strengthens our IP position

Anteo has several projects in advanced development and adds to its deal pipeline continuously

Anteo is set up for Growth


•  Mix&Go is a proprietary platform technology with broad applicability in diagnostics, life sciences, bioseparations and beyond

•  Mix&Go is proven, licensed and gaining significant traction in commercial markets

•  Mix&Go products provide easy access and credibility for customers

•  Strong near term value drivers

•  Focus on diagnostics and life sciences with expansion into bioseparations provides Anteo significant revenue opportunities

•  Ready to develop opportunities in additional markets and execute long term potential

•  Strong leadership - Board and management team in place to drive growth

•  Global team, resources and network to capitalise on growth opportunities

Contact Information Thank you very much for you interest in Anteo Diagnostics

For more information please contact:


Dr. Geoff Cumming, CEO E: [email protected] M: +61 417 203 021

Or download Anteo Investor Relations App for latest ASX news, share price and important company updates. Available under Anteo IR at App store and Google play

Anteo Technologies - New York presentation 2015

Healthcare

Transcript of Anteo Technologies - New York presentation 2015